Back to Careers

Meredith Brown-Tuttle

linkedin-icon-green

Meredith Brown-Tuttle has written and coordinated numerous drug and biologic
submissions to US and international regulatory agencies, developed global regulatory
strategies, and conducted worldwide regulatory intelligence.

Meredith Brown-Tuttle, RAC, FRAPS, has 31 years of industry experience from bench to clinic to
approval of both drugs and devices. Meredith has written and coordinated numerous drug and
biologic submissions to US and international regulatory agencies, developed global regulatory
strategies and conducted worldwide regulatory intelligence. She is currently both Vice
President of Regulatory & Quality at Lyric Pharmaceuticals, Inc. and a strategy/intelligence
consultant at Regulatoium. Meredith has written, managed and led over 30 successful domestic
and international IND and NDA submissions. She is a founding instructor at UC Santa Cruz
Regulatory Certificate Program and author of two books: “IND Submissions: A Primer” and
“Regulatory Intelligence 101.” Meredith graduated with a BA in biological psychology
(neuroscience) from San Jose State University.

Learn more about Meredith

LinkedIn

Back to Careers

The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of Aging

Back to Careers

Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Back to Careers

Discussing longevity insights among financial and biotech leaders from at the BioFuture Conference, Juvena CEO, Hanadie Yousef, PhD explores the role of secreted proteins in targeting chronic and age-related diseases.

Back to Careers

Mo (Mohammad) Tabrizi PhD

linkedin-icon-green

Mo (Mohammad) Tabrizi PhD joined Juvena Therapeutics in 2022, bringing over 25 years’ experience in basic research, integrative pharmacology, translational sciences, and development of protein-based biologics. Prior to Joining  Juvena Therapeutics, Dr. Tabrizi served in positions with increasing responsibilities at Large companies such as Merck Research Laboratories, AstraZeneca/Medimmune, and biotech companies such as Soteria Biotherapeutics, Acendis pharma and Abgenix. His product development experience spans many therapeutic areas including oncology, immune-oncology, and inflammatory diseases.

He has been an author or co-inventor on more than 50 original papers, reviews articles, published books and patents.  Dr. Tabrizi has been an invited speaker to numerous national and international conferences. Dr. Tabrizi received his bachelor’s degree in Pharmacy from University of Houston (Summa Cum Laude) and his PhD from University at Buffalo, State University of New York (SUNY) in Pharmaceutical Sciences. He completed a postdoctoral training in pharmacology at University of New York at Buffalo (SUNY) with a focus on therapeutics.

 

Learn more about Mohammad

LinkedIn

Back to Careers

Juvena Therapeutics is recognized for its transformative science that targets unmet medical needs as well as for the quality of its management team as part of the Emerging Company Showcase at the prestigious Life Sciences Summit.

Back to Careers

BioCom California, the leading life science industry organization in California recognizes Juvena’s CEO, Dr. Hanadie Yousef for her achievements, vision and scientific and business accumen in its Life Science Catalyst Awards.

Back to Careers

To help drive change in biotech, Dr. Hanadie Yousef joined the industry’s leading women CEOs and investors at  the first joint Women Investors and CEOs networking event hosted by Sofinnova Investments and Cowen. Together these women are driven to create positive change in the industry, improving diversity among biotech c-suite and investors and supporting one another.

Back to Careers

Tejaswini Ganapathi

linkedin-icon-green

Tejaswini Ganapathi joined Juvena Therapeutics in October 2022. She is working on development of AI models that power Juvena’s protein discovery for targeted in vitro screening, and will be exploring the application of AI to other aspects of the company’s drug pipeline as well. 

Tejaswini has extensive experience in machine learning algorithm development both in research and production and towards building end to end ML systems. Her industry experience spans various domains such as healthcare, medical imaging, finance and wireless networks. She has been an early employee at 2 startups with successful exits and holds ~10 patents. She pursued her graduate studies at University of Toronto and University of Texas at Austin, both specializing in machine learning. 

Outside of AI and work, Tejaswini is a RYT200 Yoga instructor, is trained in Indian Classical music and tries to contribute her time to animal rescues.

 

Learn more about Tejaswini

LinkedIn

Back to Careers

Sarah Tang

linkedin-icon-green

Sarah joined Juvena Therapeutics in October 2022 as a Senior Research Associate to contribute to Dr. Fengling Liu’s research on protein expression and purification.

She obtained her bachelor’s degree in molecular and cell biology from the University of California, Berkeley.

Before joining Juvena Therapeutics, Sarah worked as a Research Associate in the antibody discovery field, where she attained hybridoma sequences, antibody transient expression, and hit identification. Prior to transitioning to research, Sarah worked in the clinical diagnostics field as a Lab Administrative Manager. She managed lab operations while staying active on the bench.

In Sarah’s free time, she enjoys creating content for her cat’s social media, gaming with friends, and attending ballet performances.

 

Learn more about Sarah

LinkedIn